Genmab宣布Epcoritamab联合来那度胺三期试验取得积极成果

投资观察
Yesterday

Genmab A/S公布了一项三期临床试验的积极结果,该试验评估了Epcoritamab联合来那度胺在复发/难治性弥漫性大B细胞淋巴瘤患者中的疗效。数据显示,该联合疗法在无进展生存期方面取得了统计学上的显著改善。

这项名为EPCORE DLBCL-4的试验达到了其主要终点,结果显示,与对照组相比,该治疗方案可将疾病进展或死亡的风险降低高达60%。此外,Epcoritamab联合来那度胺展现出了一致的安全性特征。

Genmab及其合作伙伴艾伯维公司计划就EPCORE DLBCL-4的试验结果与监管机构进行沟通。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10